Leukemia Research Study
|
Autologous NK cell infusions in treatment resistant CLL and CML
|
If you (or someone you know) has CLL or CML that is not responding to standard treatments, you may be able to participate in our phase 1 clinical trial designed to evaluate the safety of a new type of cell transplant. Specifically, we are testing the safety and tolerability of the infusion of one type of your own white blood cells called NK cells.
In this research project your NK cells will be collected, reproduced in large numbers in the laboratory and then given back to you as an infusion. Before the cells are given back, you will receive two chemotherapy agents: pentostatin, to suppress your immune system and prevent it from attacking the infused NK cells, and bortezomib, to increase the anti-tumor activity of the NK cells. You will also receive the drug interleukin-2 to maintain NK cell activity. You are required to return to the Clinical Center for frequent safety monitoring over a 7 week period of protocol participation. If you respond you may have the option to continue NK cell infusions.
To find out if you qualify, please call us toll free at 1-800-411-1222 (TTY 1-866-411-1010). Our email address is BloodStudy@nhlbi.nih.gov
|
|
 
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Escalating Doses of ON 01910.Na for Leukemia
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating a new treatment for chronic lymphocytic leukemia (CLL) and Hairy cell Leukemia. The study drug, ON01910.Na is classified as mitotic inhibitor and works by interrupting the life cycle of leukemia cells. Consenting subjects will receive 2 days of drug infusion once every other week (1 cycle) for a minimum of 2 cycles. Subjects without toxicity will have the option to continue the regimen for 2 additional cycles, after which if there is evidence of response, subjects may continue the regimen indefinitely.
If you are between the ages of 18 and 99 and have been diagnosed with CLL and have failed to respond to, relapsed following, are not eligible for, or opted not to participate in other standard of care treatment options you may be able to participate in a clinical trial. This study will determine what dose and which dosing schedule of this new drug is safe. We will also evaluate whether or not this drug can slow progression of your illness, improve blood counts, and/or reduce the need for transfusions of blood and/or platelets.
To find out if you qualify, please call our study coordinator at 301-402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Lenalidomide (Revlimid) in CLL and SLL
|
Hematologists at the National Heart, Lung, and Blood Institute are investigating an experimental treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The study drug--an immune modulator that may block blood vessel growth in cancers--may help normalize blood counts, reduce leukemia-related symptoms, decrease risk of infections and/or improve quality of life and long-term survival. Consenting subjects will take an oral dose of lenalidomide daily for 3 weeks and then no medication for 3 weeks and repeat the regimen 4 times (4 cycles). Response will be measured at 24 weeks. Responding patients will have the option to continue the regimen for 2 additional cycles (if in CR after 4 cycles) or 4 cycles (if in PR after 4 cycles).
If you have been diagnosed with CLL or SLL , have already been treated for CLL or SLL and are 21 years or older, you may be able to participate in this clinical trial. To find out if you qualify, please call our study coordinator at 301-402-0797 or email us atBloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Measurement of residual disease following treatment for CML
|
Researchers at the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) are conducting laboratory studies on blood and bone marrow from subjects with chronic myelogenous leukemia (CML) in order to in order to compare the level of disease that remains after a stem cell transplant with a level of disease remaining after treatment with Gleevec.
If you or someone you know has been diagnosed and treated for CML you (they) may be able to participate in this sample procurement protocol. Compensation for sample collection procedures is provided.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Natural History of MBL, CLL and SLL
|
The Hematology Branch of the National Heart, Lung, and Blood Institute is conducting a clinical study for previously untreated patients with Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) or Monoclonal B cell lymphocytosis (MBL). Although all three diseases are considered a type of blood cancer involving B-lymphocytes, CLL involves the peripheral blood, SLL mostly involves the lymph nodes, and MBL is thought to be the earliest diagnostic stage of CLL/SLL.
Most patients with CLL/SLL/MBL do not require treatment at the time of diagnosis and are observed following a "watch and wait" approach. This study provides state of the art diagnostic workup, regular follow-up monitoring, and sample collection during the "watch and wait" period. If treatment becomes necessary, patients will receive information on possible standard treatment options and research studies available at NIH.
If you choose to participate, you will undergo tests and procedures designed to evaluate the status of your disease. You will also have the opportunity to donate blood and tissue samples that will be used in laboratory research experiments designed to help us better understand MBL/CLL/SLL.
If you or someone you know has been diagnosed with MBL, CLL, or SLL you (they) may be able to participate in this study. To find out if you qualify, please contact our research coordinator at (301) 402-0797 or email us at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Partially Matched DLI to Treat Relapsed Leukemia
|
If you or someone you know is diagnosed with ALL, AML, or CML and have relapsed within 6 months of receiving a stem cell transplant, you may be able to participate in our clinical trial designed to evaluate the effectiveness of a partially HLA matched infusion of donor lymphocytes (DLI). Specifically, we are testing whether giving an infusion of donor lymphocytes from a partially matched family member will maximize the antileukemia effect of following an HLA matched allogeneic stem cell transplant. To achieve at least temporary engraftment of the DLI and disease control, cyclophosphamide and fludarabine immunosuppression will be given prior to the DLI.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Selectively Depleted Stem Cell Transplant to Treat Leukemia
|
If you or someone you know is diagnosed with ALL, AML, CLL, or CML, you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether the special treatment of donor stem cells and immune cells will reduce complications (Graft versus host disease) and improve transplant outcome. You must have an HLA matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant and T Cell Add Back to Treat Leukemia
|
If you or someone you know is diagnosed with acute lymphocytic leukemia (ALL), acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), or chronic myrlogenous leukemia (CML), you may be able to participate in our clinical trial designed to investigate methods of making stem cell transplant procedures safer and more effective. Specifically, we are testing whether special treatment of donor stem cells and delaying the transfusion of donor immune cells will reduce complications and improve transplant outcome. You must have an HLA-matched brother or sister who is willing to participate as a donor in order to participate in this study.
To find out if you qualify, please contact our research coordinator at (301) 496-3841 or by email at BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
Leukemia Research Study
|
Stem Cell Transplant for High Risk Patients with Leukemia
|
If you have been diagnosed with ALL, AML, CLL, CML, or CMML you may be able to participate in a stem cell transplant clinical trial designed to evaluate methods to decrease graft-versus-host disease, promote engraftment, and improve immune system recovery following a bone marrow stem cell transplant procedure.
You must have an HLA-matched family member to participate. You will be given chemotherapy followed by a transfusion of stem cells and lymphocytes from your donor, which will replace your immune system with the immune system of your healthy donor. Post-transplant therapy is designed to reduce the risk of graft-versus-host disease.
We do the blood testing free of charge to see if your family member is a match. We pay for all medical costs related to the transplant procedure. You must be available to live near NIH for approximately 3 months. We also provide a daily allowance to help with living expenses while you are on the study and living away from home.
To inquire about eligibility, contact our research coordinator (301) 594-8013 or by e-mail: BloodStudy@nhlbi.nih.gov
|
|
|
|
|
|
Protocol Information |
|
|
|
Disease and Treatment Information |
|
|
|
Support Groups |
|
| |
|
|
|
|
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute